CRA and AA declare that there are no relationships or activities that might bias, or be perceived to bias, their work
There is also the complex intertwined cost reality that, while there will be an obvious increase in cost when covering GLP-1s, plan sponsors also need to consider the potential longer-term benefits for members improved health such as the avoidance of disease complications related to obesity
Engin AB, Engin ED, Engin A
The findings indicate that: 67% of Omada members were persistent on their medication at one year and experienced weight loss comparable to clinical trials Average weight loss at one year in the program was 18.4% for members persistent on medication and 13.1% for members who discontinued before one year In terms of engagement, members completed more than 10 actions a week on average This data suggests that providing the right kind of support to promote GLP-1 persistence can help patients achieve clinical trial-level weight loss, setting the stage for cardiometabolic disease risk reduction
Because you're our patient and not the insurer's, there's no middleman steering your care we can recommend the most effective, current treatments for your goals, including the compounded medications and advanced peptides insurance usually won't cover
